717906-56-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
(R)-N-Boc-1-(5-(trifluoroMethyl)pyridin-2-yl)pyrrolidin-3-aMine is utilized as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and functional groups contribute to the development of new compounds with therapeutic or pesticidal properties.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-N-Boc-1-(5-(trifluoroMethyl)pyridin-2-yl)pyrrolidin-3-aMine serves as a versatile building block. Its structural features allow for the creation of new synthetic routes and the development of a wide range of organic compounds.
Used in Drug Discovery and Development:
Due to its potential biological activity and the interest it has attracted in the scientific community, (R)-N-Boc-1-(5-(trifluoroMethyl)pyridin-2-yl)pyrrolidin-3-aMine is employed in drug discovery and development. Researchers explore its properties to identify new therapeutic agents or to improve existing ones.

Upstream product

• 52334-81-3 2-chloro-5-trifluoromethylpyridine 
• 122536-77-0 3-N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine 

Downstream Products

• 501951-42-4 N-(2-bromophenyl)-N'-[((R)-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea 
• 202267-15-0 (R)-1-(5-trifluoromethylpyridin-2-yl)pyrrolidin-3-ylamine 

Relevant academic research and scientific papers

Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

Small molecule antagonists of the vanilloid receptor TRPV1 (also known as VR1) are disclosed. Pyrrolidinyl ureas such as 8 and 15 (SB-705498) emerged as lead compounds following optimisation of the previously described urea SB-452533. Pharmacological studies using electrophysiological and FLIPR-Ca2+-based assays showed that compounds such as 8 and 15 were potent antagonists versus the multiple chemical and physical modes of TRPV1 activation (namely capsaicin, acid and noxious heat). Furthermore, 15 possessed suitable developability properties to enable progression of this compound into in vivo studies and subsequently clinical development.

ANILINE DERIVATIVES

The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds represented by the formulas (A), (B), (C), (E) and (H) : wherein each symbol is as defined in the specification, or a pharmac

UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN

Certain compounds of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, P, P', n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine.